Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Sep 24, 2014; 4(3): 153-167
Published online Sep 24, 2014. doi: 10.5500/wjt.v4.i3.153
Published online Sep 24, 2014. doi: 10.5500/wjt.v4.i3.153
Methodological aspects of anti-human leukocyte antigen antibody analysis in solid organ transplantation
Andrew L Lobashevsky, Histocompatibility Laboratory, Department of Medicine, School of Medicine, Indiana University, Indianapolis, IN 46202, United States
Andrew L Lobashevsky, Histocompatibility Laboratory, Methodist Hospital, Indiana University Health Inc., Indianapolis, IN 46202, United States
Author contributions: Lobashevsky AL solely contributed to this paper.
Correspondence to: Andrew L Lobashevsky, MD, PhD, Associate Professor, Director, Histocompatibility Laboratory, Department of Medicine, School of Medicine, Indiana University, 702 Barnhill Dr., Room #0615, Indianapolis, IN 46202, United States. alobashe@iuhealth.org
Telephone: +1-317-9488717 Fax: +1-317-9481108
Received: March 21, 2014
Revised: June 16, 2014
Accepted: July 25, 2014
Published online: September 24, 2014
Processing time: 217 Days and 13.1 Hours
Revised: June 16, 2014
Accepted: July 25, 2014
Published online: September 24, 2014
Processing time: 217 Days and 13.1 Hours
Core Tip
Core tip: In solid organ transplantations the graft outcomes critically depend on the degree of human leukocyte antigen (HLA) matching between the donor and recipient. Although the cellular component of the allogeneic immune response to the transplanted tissue plays a key role, the contribution of antibodies should not be underestimated. The detection of anti-HLA class I and class II antibodies is an important component of the initial work-up of a potential transplant candidate. The introduction of new highly sensitive technologies such as solid-phase based technologies has had a tremendous effect on organ allocation and immunomodulation strategies.